No retraction, correction or concern found when last checked on Oct 21, 2026.

Roles of polyunsaturated fatty acids, from mediators to membranes

Takeshi Harayama, Takao Shimizu

Journal of Lipid Research · 2020 · Review · CC BY

doi:10.1194/jlr.r120000800

Abstract

PUFAs, such as AA and DHA, are recognized as important biomolecules, but understanding their precise roles and modes of action remains challenging. PUFAs are precursors for a plethora of signaling lipids, for which knowledge about synthetic pathways and receptors has accumulated. However, due to their extreme diversity and the ambiguity concerning the identity of their cognate receptors, the roles of PUFA-derived signaling lipids require more investigation. In addition, PUFA functions cannot be explained just as lipid mediator precursors because they are also critical for the regulation of membrane biophysical properties. The presence of PUFAs in membrane lipids also affects the functions of transmembrane proteins and peripheral membrane proteins. Although the roles of PUFAs as membrane lipid building blocks were difficult to analyze, the discovery of lysophospholipid acyltransferases (LPLATs), which are critical for their incorporation, advanced our understanding. Recent studies unveiled how LPLATs affect PUFA levels in membrane lipids, and their genetic manipulation became an excellent strategy to study the roles of PUFA-containing lipids. In this review, we will provide an overview of metabolic pathways regulating PUFAs as lipid mediator precursors and membrane components and update recent progress about their functions. Some issues to be solved for future research will also be discussed.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

1The importance of PUFAs in health and disease gained general attention, as exemplified by the belief that eating more ω-3 PUFAs is good for health. PUFAs are fatty acids that have two or more double bonds, which can be illustrated as XX:Yω-Z (XX, Y, and Z are carbon number, double bond number, and the position of the first double bond from the methyl end, respectively). They cannot be synthesized endogenously in mammals, except for mead acid (20:3ω-9), which is produced under PUFA deficiency. Therefore, PUFAs are essential nutrients that have to be obtained from the diet. While important PUFAs, such as AA (20:4ω-6) and DHA (22:6ω-3), can be directly taken up from the diet, they can also be converted from other PUFAs endogenously. The liver has a major contribution in this process, where dietary linoleic acid (LA; 18:2ω-6) and α-linolenic acid (18:3ω-3) are metabolized into other PUFAs by desaturases, elongases, and peroxisomal β-oxidation (Fig. 1A). Peroxisomes are critical for the final step of DHA synthesis, and their dysfunction leads to the accumulation of the otherwise minor intermediate PUFA, tetracosahexaenoic acid (24:6ω-3). Analysis of mice lacking elongases or desaturases revealed PUFA functions in brain, metabolic tissues, reproductive organs, and blood cells. While some of the phenotypes of these mice were seen only when fed PUFA-deficient diets, others, such as the lean phenotype of Fads1-deficient mice, were observed even when the diets were PUFA sufficient. This supports the importance of obtaining sufficient levels of PUFAs both from the diet and from endogenous conversion. Importantly, the possibility to rescue the phenotypes by dietary intervention was dependent on which PUFA to give, clearly demonstrating the nonredundancy in their functions (Table 1). The importance of PUFAs has also been analyzed by feeding them in cell culture, revealing important roles in osteogenesis and mechanosensing, among many others. While such in vivo and in cellulo experiments support the biological importance of PUFAs, understanding the molecular mechanisms of PUFA functions remains challenging.

2PUFAs have two major modes of action: precursors of signaling lipids (lipid mediators) and building blocks of membrane lipids. It is thus important to recognize the pleiotropic functions of PUFAs and dissect their modes of action. This necessity made PUFA research an exciting multidisciplinary field at the interface of biology, biophysics, and chemical biology. Here, we will highlight the complex metabolism of PUFAs, the investigation of which elucidated PUFA functions, as lipid mediators and in membranes.

PUFA-DERIVATIVES IN SIGNALING

3Multiple lipid mediators are produced downstream of glycerophospholipid (GPL) synthesis (Fig. 1B). They include metabolites of PUFAs (e.g., eicosanoids, docosanoids) and lipids with esterified PUFAs [e.g., 2-arachidonoylglycerol (2-AG)], collectively termed PUFA-derivatives here (Fig. 2A).

Diversity of PUFA-derivatives

4AA is mainly esterified at the sn-2 position of GPLs, such as PC, PE, PS, phosphatidylglycerol, and PI. PI is especially rich in AA (with stearic acid at the sn-1 position), while other GPLs have more diverse acyl-chains. After being released from GPLs by phospholipase A2 (PLA2) enzymes (Fig. 1B, arrow 1), AA is converted into more than a hundred different lipid mediators (eicosanoids) by cyclooxygenases, lipoxygenases, cytochrome P450 enzymes, and specific synthases. Among PLA2s, cytosolic PLA2α (cPLA2α) causes translocation from cytosol to perinuclear membranes upon various stimuli and is especially important for eicosanoid production. Analyses of cPLA2α using hydrogen/deuterium exchange mass spectrometry and molecular dynamics revealed how the enzyme uses its C2 domain to bind membranes upon calcium binding, to which atomistic details were brought by a recent structural analysis of the C2 domain complexed with a PC membrane. In addition to perinuclear membranes, cPLA2α localizes to the base of primary cilia, where it releases AA to regulate ciliary trafficking of Smoothened, the signal transducer of the Sonic Hedgehog pathway. Mice lacking cPLA2α have drastic decreases in eicosanoids and are protected from disease models that include anaphylaxis, asthma, and experimental allergic encephalomyelitis. However, they also display abnormalities in labor and synaptic plasticity, demonstrating the pleiotropy of eicosanoid functions. The implication of other phospholipases in the release of PUFAs from GPLs is well recapitulated in another review. While AA release from GPLs has been studied intensively, other sources of AA for eicosanoid synthesis have been documented, such as triglycerides and 2-AG (Fig. 1B, arrows 2 and 3). Eicosanoids produced downstream of the hydrolysis of 2-AG (which is also a lipid mediator) by monoacylglycerol lipase are especially important in the brain, with implications in neuroinflammation and fever responses. Blockade of this pathway reduces eicosanoid production and ameliorates a mouse model of Alzheimer’s disease. This pathway is also active outside the brain, as has been shown in a model of hepatic injury. PI, being rich in AA, is a good source of 2-AG, and might feed efficiently into this pathway (Fig. 1B).

5Eicosanoids are only one part of the diverse repertoire of PUFA-derivatives; other PUFAs are converted into lipid mediators through similar pathways. Those generated from the ω-3 PUFAs, EPA and DHA, are generally regarded as pro-resolving lipid mediators, in contrast to the pro-inflammatory eicosanoids. This view is oversimplified though, and some ω-3 PUFA-derivatives promote allergic responses while the eicosanoid lipoxin A4 is pro-resolving. Recent investigations revealed important roles of the secreted PLA2 group 2D (PLA2G2D) in the release of PUFAs, including ω-3 PUFAs, from extracellular GPL substrates to generate pro-resolving lipid mediators. PLA2G2D deficiency reduces the production of pro-resolving lipid mediators in the lymph nodes and delays the resolution of contact dermatitis in mice. In addition, DHA released by M2-type macrophage-derived PLA2G2D in adipose tissues promotes the generation of beige adipocytes. DHA acts as a ligand for free fatty acid receptor 4, which is expressed in primary cilia of preadipocytes and regulates adipogenesis. Thus, the ω-3 PUFA DHA has various effects on adipocyte functions. Together with its anti-inflammatory function on macrophages, the pleiotropic roles of DHA as a lipid mediator contribute to metabolic health.

6Lipid mediators containing esterified PUFAs are also numerous, such as the cannabinoid receptor ligands 2-AG and anandamide (N-arachidonoylethanolamine). They mediate retrograde signaling in neuronal synapses and regulate appetite and pain, while having peripheral functions in the immune system as well. Another example is 2-arachidonoyl LPI, which is synthesized from PI via the action of phospholipase A1. One of its functions is to regulate lymphocyte migration as a ligand for the G protein-coupled receptor (GPCR) GPR55. In addition to this already exhaustive list, novel PUFA-derivatives and synthetic pathways are continuously discovered, such as the hemiketal eicosanoids and fatty acid esters of hydroxy fatty acids (FAHFAs).

Signaling by PUFA-derivatives

7PUFA-derivatives signal through their receptors, which include GPCRs, ion channels, and nuclear receptors (the last two tend to be more promiscuous). So far, many GPCRs are proposed as PUFA-derivative receptors (Fig. 2B), but conflicting results are often reported between studies using different assays, and some might be invalidated in the future. In addition, the presence of multiple receptors for the same ligand [e.g., four prostaglandin E2 receptors] or the presence of nonlipid ligands for proposed lipid receptors [e.g., GPR132, also termed G2A, reported to be a proton sensor and a receptor for 9-hydroxyoctadecadienoic acid; chemerin being a protein ligand for the proposed receptor of resolvin E1] should be taken into account when considering the functions of PUFA-derivatives. For example, GPR37 is proposed as the receptor for DHA-derived neuroprotective and anti-inflammatory protectin D1, while the peptide prosaptide also acts through the same receptor and has similar neuroprotective roles. Therefore, it will be important for future studies, especially for PUFA-derivatives that do not have a long history of research, to investigate whether the effects of receptor blockade correspond to those of interference with ligand synthesis.

8For PUFA-derivatives having well-validated receptors, such as the eicosanoid prostaglandin E2, genetic disruption or inhibitors can be used to investigate in vivo functions. Prostaglandin E2 has been implicated in colon cancer through multiple genetic studies, with consistent phenotypes between mutant mice of synthetic enzymes and receptors. In a recent study, single-cell RNA sequencing was used to identify a rare fibroblast population producing prostaglandin E2, which promotes tumor initiation by activating Yap nuclear localization in stem cells that are in proximity. In the same study, fibroblast-produced prostaglandin E2 was shown to be part of a regenerative program after intestinal damage, thereby revealing the correct biological functions of this lipid mediator. With reliable information about synthetic enzymes and receptors, single-cell RNA sequencing approaches might be used similarly in different contexts to identify PUFA-derivative functions.

9Our understanding of PUFA-derivative signaling advanced especially in the context of structural biology. The number of reported GPCR structures is expanding, such as the crystal structures of leukotriene B4 receptor BLT1 and the prostaglandin D2 receptor DP2. The structure of prostaglandin E2 receptor EP3 was solved in the presence of its endogenous ligand, revealing critical insights into ligand recognition. Molecular docking and molecular dynamics simulations have also been used to investigate the recognition of endogenous ligands for other receptors. The structure of the cannabinoid receptor CB1 has been solved in multiple states, bound to inverse agonists, antagonists, agonists, and allosteric modulators or in complex with trimeric Gi protein, revealing the structural rearrangements upon ligand binding that lead to signaling events. The structural characteristics of some GPCRs (e.g., DP2, EP4, TP, and LPA6), such as the presence of an occluded extracellular surface and side openings between transmembrane helices, suggested that the amphiphilic lipid ligands reach the receptor by lateral diffusion in the plasma membrane rather than directly from outside of the cells. On the other hand, BLT1 ligand binding pocket is open on the extracellular surface, thus different lipid ligands reach their receptors in distinct ways. It will be interesting to understand how these different receptor-accessing modes affect the functions of PUFA-derivatives, such as their effective concentrations, the recognition of their concentration gradients, and their autocrine or paracrine behavior.

10To conclude, signaling by PUFA-derivatives is complex due to their diversity, the presence of multiple synthetic sources, and the multiple receptors of a single ligand. Nevertheless, genetic studies of enzymes and receptors unveiled various roles of PUFA-derivatives, and structural analyses revealed atomistic insights of their functions. Methodological advances are ongoing to detect lipid mediators comprehensively and to unveil the spatiotemporal regulation of receptor activation in vivo. It will be important to solve controversies regarding the assignment PUFA-derivative receptors, and researchers are encouraged to publish more replication studies (both positive and negative). With more reliability in receptors, we will be able to understand the degree to which PUFAs affect pathophysiological conditions as lipid mediator precursors, which might reveal novel therapeutic targets.

Regulation of PUFA-GPLs

11While dietary uptake affects whole-organism PUFA supply, tissue-specific functions of GPLs containing PUFAs (PUFA-GPLs) require factors that regulate their tissue distribution. The incorporation of PUFAs at the GPL sn-2 position, their main localization, is catalyzed by lysophospholipid acyltransferases (LPLATs) (Fig. 1B, bold arrows). These enzymes use lyso-GPLs and acyl-CoAs as substrates. During GPL de novo synthesis, lysophosphatidic acid acyltransferases (LPAATs) are the LPLATs that acylate the sn-2 position and generate the common precursor PA, which is further converted to other GPLs. Acyl-chains of individual GPLs can be remodeled in the “Lands’ cycle,” where one acyl-chain is removed and another one is reincorporated by other LPLATs.

12At least for PC (the most abundant GPL), expression levels of LPLATs contribute to tissue differences in PUFA-GPL levels, where LPAATs and other LPLATs have different roles. LPAATs enable the accumulation of LA and DHA in PC (and possibly to other GPLs), while AA is mainly incorporated during the Lands’ cycle. This conclusion is based on the correlation between PC acyl-chain composition and LPLAT substrate selectivity in various tissues, which was later validated in part by genetic studies. Indeed, disruption of the DHA-preferring AGPAT3 (also termed LPAAT3) drastically reduces DHA-containing GPLs (DHA-GPLs), while loss of the Lands’ cycle LPLATs, LPCAT3, and MBOAT7 (also termed LPIAT1) lowers AA levels in PC, PE, PS, and PI, respectively. Enzyme activity measurements suggest the presence of LPAAT enzyme(s) regulating LA levels, but the molecular identity of the enzyme(s) remains to be identified. Thus, LPLATs regulate PUFA levels and tissue distribution, with clearly distinct contribution depending on the individual PUFA. High AA levels in PI might assist the PI cycle (Fig. 1B), where the PI head group is sequentially modified for signaling purposes, because some enzymes of the cycle prefer AA-containing substrates.

13While it is clear that LPLATs have a strong impact on the levels of PUFAs found in GPLs of different tissues, factors that affect tissue supply of PUFAs also exist. For example, MFSD2A is a lipid transporter required for DHA accretion in the brain. Importantly, MFSD2A does not transport free DHA, but rather lyso-PC that contains DHA (DHA-lyso-PC). Thus, DHA-lyso-PC in the bloodstream is a critical source for brain DHA. While such a selectivity was already reported, the identification of MFSD2A provided clear molecular mechanisms. Strategies for improved DHA delivery to the brain are developing based on this discovery, which might be tested for a therapeutic potential in neuronal diseases where DHA levels are decreased. Another factor affecting brain DHA levels is PE methyltransferase, which converts PE into PC in the liver. PE methyltransferase has preference to DHA-containing PE (DHA-PE). Thus, DHA delivery to the brain is a multistep process, requiring the conversion of DHA-PE into DHA-PC in the liver, and then its conversion into DHA-lyso-PC, which is finally taken up by MFSD2A. The mechanisms regulating DHA-PE levels and the enzymes required for DHA-lyso-PC synthesis remain to be clarified. For the latter, phospholipase A1 activity would be required, for which hepatic lipase and endothelial lipase are good candidates. The identification of other factors affecting tissue-specific PUFA uptake will be of great relevance. For example, fatty acid transporter protein 2 was recently found to affect AA uptake in neutrophils. It will be important to investigate how specifically this transporter and other related ones affect PUFA levels in various tissues.

Mechanisms of PUFA functions in membranes

14PUFAs in GPLs have a higher structural plasticity than saturated fatty acids or MUFAs and can adopt highly kinked shapes. Consequently, PUFA-GPLs increase membrane disorder and affect their physical properties (Fig. 3A–D). Because MUFAs also induce disorder, we need to discuss PUFA functions with care and evaluate whether their effects on membrane physical properties differ from those of MUFAs in a biologically relevant manner. Also, PUFA-GPLs affect many physical properties simultaneously, and it remains difficult to know which ones, or which combinations of them, are important.

Fluidity.

15PUFA-GPLs are thought to increase membrane fluidity. While this is often proposed as a mechanism for PUFA functions, it is rarely shown quantitatively that the gain of fluidity (here defined as the speed of molecules’ diffusion and rotation) by PUFAs (compared with MUFAs) is sufficient to explain a phenomenon. The role of PUFAs in fluidity regulation has even been questioned. A recent study combined theoretical and experimental approaches to demonstrate that bacterial respiration is a diffusion-limited process and that MUFAs have quantitatively enough impact on this process. In another study, researchers combined reconstitution assays, biophysical measurements, and molecular dynamics simulations, and found that the yeast sensor for membrane unsaturation and transcription factor Mga2 is not affected by fluidity per se but rather by depth-dependent membrane packing. This study is a good example of why it is oversimplified to explain all the functions of unsaturated lipids through membrane fluidity. Therefore, future investigations about PUFA functions that rely on fluidity should be conducted carefully, as was done in the aforementioned studies.

Thickness.

16The disorder induced by PUFA-GPLs and MUFA-GPLs makes membranes thinner when compared with saturated fatty acid-GPLs (Fig. 3B). Membrane thickness affects the localization and function of transmembrane proteins, which is a possible mechanism for PUFA functions. It should be noted that highly unsaturated PUFAs are often longer than MUFAs, thus PUFA-GPLs do not necessarily make membranes thinner than MUFA-GPLs do.

Packing defects.

17Packing defects are water-accessible voids in the hydrophobic part of membranes, which accumulate in the presence of unsaturated lipids or conical lipids, or upon membrane bending (Fig. 3C). Protein amphipathic helices can interact with membranes through packing defects, which is used as a strategy to sense vesicles with different lipid compositions. While GPLs with MUFAs or PUFAs both generate packing defects, PUFA-GPLs make shallower ones, due to their structural flexibility. The depth of packing defects affects the binding of amphipathic helices with various side chains; thus PUFA-GPLs might regulate protein-membrane interactions.

Bending rigidity.

18PUFA-GPLs make membranes more flexible than MUFA-GPLs (Fig. 3D). This is attributable to the ability to reduce packing defects upon bending (and possibly to thickness). Thus, PUFAs affect processes where membrane bending occurs, as has been shown for endocytosis. Bending rigidity is a plausible mechanism for in vivo PUFA functions, as will be explained later. Importantly, only PUFA-GPLs present at the convex leaflet of a bent membrane reduce rigidity, which is consistent with the asymmetrical distribution of PUFA-GPLs in the plasma membrane, if considering endocytosis.

Protein conformation.

19Lateral pressure profiles illustrate local forces that are applied, for example to a membrane protein, depending on the depth in the membrane. Double bond positions in GPLs affect this property, which can change membrane protein conformation (Fig. 3E). The conformational flexibility of PUFAs could also assist dynamic changes in membrane protein conformation.

Chemical properties.

20Not only the physical properties but also the chemical properties (e.g., oxidative property) of PUFA-GPLs mediate their functions. One example is ferroptosis, which is a form of cell death triggered by peroxidized PUFA-GPLs and is investigated as a potential anti-cancer strategy.

Roles of membrane PUFAs

21Many functions of PUFA-GPLs were unveiled through LPLAT research (Table 1). AGPAT3-deficient mice, which have reduced DHA-GPLs, display spermatogenesis defects and retinal dysfunctions. Indirect evidence suggests that DHA-GPLs, by reducing bending rigidity, promote the formation of strongly bent membranes during spermatogenesis (for the removal of cytoplasm by Sertoli cells by tubulobulbar complex) and during maturation of rhodopsin-containing retinal disc membranes, although the role of DHA-derived lipid mediators (collectively termed docosanoids) in these processes is also possible.

22LPCAT3-deficient mice have specific reductions in GPLs containing AA (AA-GPLs) and are neonatally lethal due to enterocyte dysfunction and malnutrition, which are triggered by overaccumulation of triglycerides in the cytosol derived from mother’s milk. Liver-specific LPCAT3 deficiency leads to hepatic steatosis under a high-fat diet. These phenotypes do not match with those of known eicosanoid receptor- or eicosanoid synthetic enzyme-deficient mice, and basal eicosanoid levels are unchanged in tissues from LPCAT3-deficient mice. This suggests that AA-GPLs, and not eicosanoids, are important for triglyceride clearance from enterocytes and hepatocytes. Indeed, triglycerides surrounded by AA-GPLs are better transported by microsomal triglyceride transfer protein, which is critical for secretion of triglycerides and lipoprotein production. Therefore, the phenotypes of LPCAT3-deficient mice revealed previously unrecognized functions of PUFA-GPLs at the interface between the cytosol and triglycerides surrounded by endoplasmic reticulum leaflets. Further studies revealed that PUFA-PCs reduce the surface tension at the interface between water and triglycerides and affect the budding of lipid droplets in vitro. It will be interesting to investigate the relationship between this observation and the phenotypes of LPCAT3-deficiency. In addition to these triglyceride-related phenotypes, LPCAT3 deficiency in intestinal stem cells causes the overproduction of cholesterol, which further leads to cellular overproliferation. This overproliferation enhanced tumor formation in an Apcmin genetic background (a mouse model of colon cancer). While the implication of sterol regulatory element-binding protein 2 was shown in this process, detailed molecular mechanisms connecting LPCAT3, AA-GPLs, and cholesterol regulation remain to be solved. A role of LPCAT3 in adipocyte differentiation was also reported. Using 3T3-L1 cells as a model, knockdown of LPCAT3 by shRNA decreased PUFA-GPLs (note that in contrast to other reports, DHA-GPLs also changed) and inhibited adipogenesis. The Wnt/β-catenin pathway was activated upon LPCAT3 knockdown, the inhibition of which restored adipogenesis. This makes a potential link between AA-GPLs and adipogenesis through Wnt/β-catenin. However, regulatory roles of eicosanoids in adipogenesis have also been documented, thus it remains to be established whether AA-GPLs regulate the process.

23MBOAT7 deficiency leads to defects in neuronal migration and neurite outgrowth, leading to abnormal brain morphology in mice. Rare mutations in human MBOAT7 also cause neurodevelopmental defects. MBOAT7 deficiency decreases AA levels not only in PI but also in phosphoinositides. Quantitative changes in total levels of phosphoinositides are also reported. It is therefore possible that aberrant signaling by phosphoinositides is involved in the outcomes of MBOAT7 deficiency, but effector proteins that can discriminate phosphoinositide acyl-chains remain to be discovered. In line with this possibility, genetics studies in Caenorhabditis elegans suggest that PI acyl-chains affect PI 3-phosphate signaling. Genetic variants of MBOAT7 in humans are reported to affect nonalcoholic fatty liver disease, but inconsistencies are also suggested. In mice, liver-specific MBOAT7 knockdown or knockout promotes fatty liver. Triglyceride synthesis is promoted under MBOAT7 insufficiency, in part due to the higher turnover of PI (both synthesis and degradation are promoted) and the higher production of diacylglycerol thereof (see “PI cycle” in Fig. 1). It will be interesting to investigate whether phosphoinositides are also involved in the fatty liver phenotype.

24The investigation of LPLATs also revealed how PUFA-GPLs affect the functions of membrane proteins. By combining PUFA feeding and genetic manipulation of LPLATs in Caenorhabditis elegans, it was found that PUFA-GPLs regulate proteins involved in touch sensation. In another study, researchers generated transgenic worms expressing human TRPV4 (transient receptor potential vanilloid 4) to study how PUFA-GPLs affect its function. Through a combination of PUFA feeding and manipulation of LPLATs in these worms, they demonstrated a regulatory role of PUFA-GPLs (more specifically, GPLs containing PUFA epoxides) in vasodilation. These studies demonstrate the usefulness of LPLATs as a tool to discriminate the functions of PUFAs as lipid mediators or as membrane components.

Future directions

25Although it was difficult to discriminate whether PUFAs execute their functions through PUFA-derivatives or PUFA-GPLs, LPLAT research will probably help with this discrimination and make the functions of PUFA-GPLs clearer. It remains challenging to discover their precise molecular mechanisms, but many useful tools are being developed, such as proteome-wide identification of PUFA-interacting proteins, and genome-wide knockout screens. It is also important to visualize localization and movement of PUFA derivatives in the cells. Combination of these tools with the manipulation of PUFA-GPLs using LPLATs will be a promising approach to achieve a deep understanding of PUFA-GPL functions. Finally, the existence of PUFA level sensors is suggested in multiple studies, which will be important to identify. With all of these issues and others cleared, we will finally have a clear understanding about how PUFAs affect health and disease.

References 115

1.
Fulco A. J., and Mead J. F. 1959 Metabolism of essential fatty acids. VIII. Origin of 5,8,11-eicosatrienoic acid in the fat-deficient rat. J. Biol. Chem. 234: 1411–1416.
Not in our library
2.
Guillou H., Zadravec D., Martin P. G. P., and Jacobsson A. 2010 The key roles of elongases and desaturases in mammalian fatty acid metabolism: insights from transgenic mice. Prog. Lipid Res. 49: 186–199.
Not in our library10.1016/j.plipres.2009.12.002
3.
Su H. M., Moser A. B., Moser H. W., and Watkins P. A. 2001 Peroxisomal straight-chain acyl-CoA oxidase and D-bifunctional protein are essential for the retroconversion step in docosahexaenoic acid synthesis. J. Biol. Chem. 276: 38115–38120.
Not in our library10.1074/jbc.m106326200
4.
Fan Y-Y., Monk J. M., Hou T. Y., Callway E., Vincent L., Weeks B., Yang P., and Chapkin R. S. 2012 Characterization of an arachidonic acid-deficient (Fads1 knockout) mouse model. J. Lipid Res. 53: 1287–1295.
Not in our library10.1194/jlr.m024216
5.
Harauma A., Hatanaka E., Yasuda H., Nakamura M. T., Salem N., and Moriguchi T. 2017 Effects of arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid on brain development using artificial rearing of delta-6-desaturase knockout mice. Prostaglandins Leukot. Essent. Fatty Acids. 127: 32–39.
Not in our library10.1016/j.plefa.2017.10.001
6.
Moon Y-A., Hammer R. E., and Horton J. D. 2009 Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. J. Lipid Res. 50: 412–423.
Not in our library10.1194/jlr.m800383-jlr200
7.
Elovl2 ablation demonstrates that systemic DHA is endogenously produced and is essential for lipid homeostasis in mice · 2014
No notice
8.
Roqueta-Rivera M., Stroud C. K., Haschek W. M., Akare S. J., Segre M., Brush R. S., Agbaga M-P., Anderson R. E., Hess R. A., and Nakamura M. T. 2010 Docosahexaenoic acid supplementation fully restores fertility and spermatogenesis in male delta-6 desaturase-null mice. J. Lipid Res. 51: 360–367.
Not in our library10.1194/jlr.m001180
9.
Stoffel W., Hammels I., Jenke B., Binczek E., Schmidt-Soltau I., Brodesser S., Odenthal M., and Thevis M. 2014 Obesity resistance and deregulation of lipogenesis in Δ6-fatty acid desaturase (FADS2) deficiency. EMBO Rep. 15: 110–120.
Not in our library10.1002/embr.201338041
10.
Stoffel W., Holz B., Jenke B., Binczek E., Günter R. H., Kiss C., Karakesisoglou I., Thevis M., Weber A-A., Arnhold S., 2008 Δ6-Desaturase (FADS2) deficiency unveils the role of ω3- and ω6-polyunsaturated fatty acids. EMBO J. 27: 2281–2292.
Not in our library10.1038/emboj.2008.156
11.
Stroud C. K., Nara T. Y., Roqueta-Rivera M., Radlowski E. C., Lawrence P., Zhang Y., Cho B. H., Segre M., Hess R. A., Brenna J. T., 2009 Disruption of FADS2 gene in mice impairs male reproduction and causes dermal and intestinal ulceration. J. Lipid Res. 50: 1870–1880.
Not in our library10.1194/jlr.m900039-jlr200
12.
Talamonti E., Pauter A. M., Asadi A., Fischer A. W., Chiurchiù V., and Jacobsson A. 2017 Impairment of systemic DHA synthesis affects macrophage plasticity and polarization: implications for DHA supplementation during inflammation. Cell. Mol. Life Sci. 74: 2815–2826.
Not in our library10.1007/s00018-017-2498-9
13.
ELOVL2 controls the level of n-6 28:5 and 30:5 fatty acids in testis, a prerequisite for male fertility and sperm maturation in mice · 2011
Not checked
14.
Powell D. R., Gay J. P., Smith M., Wilganowski N., Harris A., Holland A., Reyes M., Kirkham L., Kirkpatrick L. L., Zambrowicz B., 2016 Fatty acid desaturase 1 knockout mice are lean with improved glycemic control and decreased development of atheromatous plaque. Diabetes Metab. Syndr. Obes. 9: 185–199.
Not in our library10.2147/dmso.s106653
15.
Levental K. R., Surma M. A., Skinkle A. D., Lorent J. H., Zhou Y., Klose C., Chang J. T., Hancock J. F., and Levental I. 2017 ω-3 Polyunsaturated fatty acids direct differentiation of the membrane phenotype in mesenchymal stem cells to potentiate osteogenesis. Sci. Adv. 3: eaao1193.
Not in our library10.1126/sciadv.aao1193
16.
Dietary fatty acids fine-tune Piezo1 mechanical response · 2019
No notice
17.
Shimizu T. 2009 Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 49: 123–150.
Not in our library10.1146/annurev.pharmtox.011008.145616
18.
Murphy R. C., and Folco G. 2019 Lysophospholipid acyltransferases and leukotriene biosynthesis: intersection of the Lands cycle and the arachidonate PI cycle. J. Lipid Res. 60: 219–226.
Not in our library10.1194/jlr.s091371
19.
Hirano Y., Gao Y-G., Stephenson D. J., Vu N. T., Malinina L., Simanshu D. K., Chalfant C. E., Patel D. J., and Brown R. E. 2019 Structural basis of phosphatidylcholine recognition by the C2-domain of cytosolic phospholipase A2α. eLife. 8: e44760.
Not in our library10.7554/elife.44760
20.
Cao J., Burke J. E., and Dennis E. A. 2013 Using hydrogen/deuterium exchange mass spectrometry to define the specific interactions of the phospholipase A2 superfamily with lipid substrates, inhibitors, and membranes. J. Biol. Chem. 288: 1806–1813.
Not in our library10.1074/jbc.r112.421909
21.
Mouchlis V. D., Bucher D., McCammon J. A., and Dennis E. A. 2015 Membranes serve as allosteric activators of phospholipase A2, enabling it to extract, bind, and hydrolyze phospholipid substrates. Proc. Natl. Acad. Sci. USA. 112: E516–E525.
Not in our library10.1073/pnas.1424651112
22.
Sonic Hedgehog Activates Phospholipase A2 to Enhance Smoothened Ciliary Translocation · 2017
Not checked
23.
Le T. D., Shirai Y., Okamoto T., Tatsukawa T., Nagao S., Shimizu T., and Ito M. 2010 Lipid signaling in cytosolic phospholipase A2α-cyclooxygenase-2 cascade mediates cerebellar long-term depression and motor learning. Proc. Natl. Acad. Sci. USA. 107: 3198–3203.
Not in our library10.1073/pnas.0915020107
24.
Uozumi N., Kume K., Nagase T., Nakatani N., Ishii S., Tashiro F., Komagata Y., Maki K., Ikuta K., Ouchi Y., 1997 Role of cytosolic phospholipase A2 in allergic response and parturition. Nature. 390: 618–622.
Not in our library10.1038/37622
25.
Murakami M. 2017 Lipoquality control by phospholipase A2 enzymes. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci. 93: 677–702.
Not in our library10.2183/pjab.93.043
26.
Dichlberger A., Schlager S., Maaninka K., Schneider W. J., and Kovanen P. T. 2014 Adipose triglyceride lipase regulates eicosanoid production in activated human mast cells. J. Lipid Res. 55: 2471–2478.
Not in our library10.1194/jlr.m048553
27.
Nomura D. K., Morrison B. E., Blankman J. L., Long J. Z., Kinsey S. G., Marcondes M. C. G., Ward A. M., Hahn Y. K., Lichtman A. H., Conti B., 2011 Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science. 334: 809–813.
Not in our library10.1126/science.1209200
28.
Fever Is Mediated by Conversion of Endocannabinoid 2-Arachidonoylglycerol to Prostaglandin E2. · 2015
Not checked
29.
A Dysregulated Endocannabinoid-Eicosanoid Network Supports Pathogenesis in a Mouse Model of Alzheimer's Disease · 2012
Not checked
30.
Cao Z., Mulvihill M. M., Mukhopadhyay P., Xu H., Erdélyi K., Hao E., Holovac E., Haskó G., Cravatt B. F., Nomura D. K., 2013 Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. Gastroenterology. 144: 808–817.e15.
Not in our library10.1053/j.gastro.2012.12.028
31.
Identification and structure elucidation of the pro‐resolving mediators provides novel leads for resolution pharmacology · 2018
No notice
32.
Serhan C. N. 2014 Pro-resolving lipid mediators are leads for resolution physiology. Nature. 510: 92–101.
Not in our library10.1038/nature13479
33.
Shimanaka Y., Kono N., Taketomi Y., Arita M., Okayama Y., Tanaka Y., Nishito Y., Mochizuki T., Kusuhara H., Adibekian A., 2017 Omega-3 fatty acid epoxides are autocrine mediators that control the magnitude of IgE-mediated mast cell activation. Nat. Med. 23: 1287–1297.
Not in our library10.1038/nm.4417
34.
Miki Y., Yamamoto K., Taketomi Y., Sato H., Shimo K., Kobayashi T., Ishikawa Y., Ishii T., Nakanishi H., Ikeda K., 2013 Lymphoid tissue phospholipase A2 group IID resolves contact hypersensitivity by driving antiinflammatory lipid mediators. J. Exp. Med. 210: 1217–1234.
Not in our library10.1084/jem.20121887
35.
Secreted Phospholipase PLA2G2D Contributes to Metabolic Health by Mobilizing ω3 Polyunsaturated Fatty Acids in WAT · 2020
Not checked
36.
Hilgendorf K. I., Johnson C. T., Mezger A., Rice S. L., Norris A. M., Demeter J., Greenleaf W. J., Reiter J. F., Kopinke D., and Jackson P. K. 2019 Omega-3 fatty acids activate ciliary FFAR4 to control adipogenesis. Cell. 179: 1289–1305.e21.
Not in our library10.1016/j.cell.2019.11.005
37.
Oh D. Y., Talukdar S., Bae E. J., Imamura T., Morinaga H., Fan W., Li P., Lu W. J., Watkins S. M., and Olefsky J. M. 2010 GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 142: 687–698.
Not in our library10.1016/j.cell.2010.07.041
38.
Donvito G., Nass S. R., Wilkerson J. L., Curry Z. A., Schurman L. D., Kinsey S. G., and Lichtman A. H. 2018 The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain. Neuropsychopharmacology. 43: 52–79.
Not in our library10.1038/npp.2017.204
39.
Tanimura A., Yamazaki M., Hashimotodani Y., Uchigashima M., Kawata S., Abe M., Kita Y., Hashimoto K., Shimizu T., Watanabe M., 2010 The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase α mediates retrograde suppression of synaptic transmission. Neuron. 65: 320–327.
Not in our library10.1016/j.neuron.2010.01.021
40.
Yamashita A., Kumazawa T., Koga H., Suzuki N., Oka S., and Sugiura T. 2010 Generation of lysophosphatidylinositol by DDHD domain containing 1 (DDHD1): possible involvement of phospholipase D/phosphatidic acid in the activation of DDHD1. Biochim. Biophys. Acta. 1801: 711–720.
Not in our library10.1016/j.bbalip.2010.03.012
41.
Sumida H., Lu E., Chen H., Yang Q., Mackie K., and Cyster J. G. 2017 GPR55 regulates intraepithelial lymphocyte migration dynamics and susceptibility to intestinal damage. J. Sci. Immunol. 2: eaao1135.
Not in our library10.1126/sciimmunol.aao1135
42.
Giménez-Bastida J. A., Shibata T., Uchida K., and Schneider C. 2017 Roles of 5-lipoxygenase and cyclooxygenase-2 in the biosynthesis of hemiketals E2 and D2 by activated human leukocytes. FASEB J. 31: 1867–1878.
Not in our library10.1096/fj.201601136r
43.
Kuda O., Brezinova M., Rombaldova M., Slavikova B., Posta M., Beier P., Janovska P., Veleba J., Kopecky J., Kudova E., 2016 Docosahexaenoic acid-derived fatty acid esters of hydroxy fatty acids (FAHFAs) with anti-inflammatory properties. Diabetes. 65: 2580–2590.
Not in our library10.2337/db16-0385
44.
Southern C., Cook J. M., Neetoo-Isseljee Z., Taylor D. L., Kettleborough C. A., Merritt A., Bassoni D. L., Raab W. J., Quinn E., Wehrman T. S., 2013 Screening β-arrestin recruitment for the identification of natural ligands for orphan G-protein–coupled receptors. J. Biomol. Screen. 18: 599–609.
Not in our library10.1177/1087057113475480
45.
N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor · 2010
No notice
46.
Hirata T., and Narumiya S. 2011 Prostanoid Receptors. Chem. Rev. 111: 6209–6230.
Not in our library10.1021/cr200010h
47.
Murakami N., Yokomizo T., Okuno T., and Shimizu T. 2004 G2A Is a proton-sensing G-protein-coupled receptor antagonized by lysophosphatidylcholine. J. Biol. Chem. 279: 42484–42491.
Not in our library10.1074/jbc.m406561200
48.
Obinata H., Hattori T., Nakane S., Tatei K., and Izumi T. 2005 Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A. J. Biol. Chem. 280: 40676–40683.
Not in our library10.1074/jbc.m507787200
49.
International Union of Basic and Clinical Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) Nomenclature, Pharmacology, and Function · 2018
No notice
50.
Bang S., Xie Y-K., Zhang Z-J., Wang Z., Xu Z-Z., and Ji R-R. 2018 GPR37 regulates macrophage phagocytosis and resolution of inflammatory pain. J. Clin. Invest. 128: 3568–3582.
Not in our library10.1172/jci99888
51.
Meyer R. C., Giddens M. M., Schaefer S. A., and Hall R. A. 2013 GPR37 and GPR37L1 are receptors for the neuroprotective and glioprotective factors prosaptide and prosaposin. Proc. Natl. Acad. Sci. USA. 110: 9529–9534.
Not in our library10.1073/pnas.1219004110
52.
Nakanishi M., Montrose D. C., Clark P., Nambiar P. R., Belinsky G. S., Claffey K. P., Xu D., and Rosenberg D. W. 2008 Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res. 68: 3251–3259.
Not in our library10.1158/0008-5472.can-07-6100
53.
Sasaki Y., Kamei D., Ishikawa Y., Ishii T., Uematsu S., Akira S., Murakami M., and Hara S. 2012 Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis. Oncogene. 31: 2943–2952.
Not in our library10.1038/onc.2011.472
54.
Kim H-B., Kim M., Park Y-S., Park I., Kim T., Yang S-Y., Cho C. J., Hwang D., Jung J-H., Markowitz S. D., 2017 Prostaglandin E2 activates YAP and a positive-signaling loop to promote colon regeneration after colitis but also carcinogenesis in mice. Gastroenterology. 152: 616–630.
Not in our library10.1053/j.gastro.2016.11.005
55.
Roulis M., Kaklamanos A., Schernthanner M., Bielecki P., Zhao J., Kaffe E., Frommelt L-S., Qu R., Knapp M. S., Henriques A., 2020 Paracrine orchestration of intestinal tumorigenesis by a mesenchymal niche. Nature. 580: 524–529.
Not in our library10.1038/s41586-020-2166-3
56.
Hori T., Okuno T., Hirata K., Yamashita K., Kawano Y., Yamamoto M., Hato M., Nakamura M., Shimizu T., Yokomizo T., 2018 Na+-mimicking ligands stabilize the inactive state of leukotriene B4 receptor BLT1. Nat. Chem. Biol. 14: 262–269.
Not in our library10.1038/nchembio.2547
57.
Wang L., Yao D., Deepak R. N. V. K., Liu H., Xiao Q., Fan H., Gong W., Wei Z., and Zhang C. 2018 Structures of the human PGD2 receptor CRTH2 reveal novel mechanisms for ligand recognition. Mol. Cell. 72: 48–59.e4.
Not in our library10.1016/j.molcel.2018.08.009
58.
Morimoto K., Suno R., Hotta Y., Yamashita K., Hirata K., Yamamoto M., Narumiya S., Iwata S., and Kobayashi T. 2019 Crystal structure of the endogenous agonist-bound prostanoid receptor EP3. Nat. Chem. Biol. 15: 8–10.
Not in our library10.1038/s41589-018-0171-8
59.
Hua T., Vemuri K., Nikas S. P., Laprairie R. B., Wu Y., Qu L., Pu M., Korde A., Jiang S., Ho J-H., 2017 Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature. 547: 468–471.
Not in our library10.1038/nature23272
60.
Toyoda Y., Morimoto K., Suno R., Horita S., Yamashita K., Hirata K., Sekiguchi Y., Yasuda S., Shiroishi M., Shimizu T., 2019 Ligand binding to human prostaglandin E receptor EP4 at the lipid-bilayer interface. Nat. Chem. Biol. 15: 18–26.
Not in our library10.1038/s41589-018-0131-3
61.
Hua T., Vemuri K., Pu M., Qu L., Han G. W., Wu Y., Zhao S., Shui W., Li S., Korde A., 2016 Crystal structure of the human cannabinoid receptor CB1. Cell. 167: 750–762.e14.
Not in our library10.1016/j.cell.2016.10.004
62.
Krishna Kumar K., Shalev-Benami M., Robertson M. J., Hu H., Banister S. D., Hollingsworth S. A., Latorraca N. R., Kato H. E., Hilger D., Maeda S., 2019 Structure of a signaling cannabinoid receptor 1-G protein complex. Cell. 176: 448–458.e12.
Not in our library10.1016/j.cell.2018.11.040
63.
Shao Z., Yan W., Chapman K., Ramesh K., Ferrell A. J., Yin J., Wang X., Xu Q., and Rosenbaum D. M. 2019 Structure of an allosteric modulator bound to the CB1 cannabinoid receptor. Nat. Chem. Biol. 15: 1199–1205.
Not in our library10.1038/s41589-019-0387-2
64.
High-resolution crystal structure of the human CB1 cannabinoid receptor · 2016
No notice
65.
Fan H., Chen S., Yuan X., Han S., Zhang H., Xia W., Xu Y., Zhao Q., and Wu B. 2019 Structural basis for ligand recognition of the human thromboxane A2 receptor. Nat. Chem. Biol. 15: 27–33.
Not in our library10.1038/s41589-018-0170-9
66.
Taniguchi R., Inoue A., Sayama M., Uwamizu A., Yamashita K., Hirata K., Yoshida M., Tanaka Y., Kato H. E., Nakada-Nakura Y., 2017 Structural insights into ligand recognition by the lysophosphatidic acid receptor LPA6. Nature. 548: 356–360.
Not in our library10.1038/nature23448
67.
Nakamura M., and Shimizu T. 2011 Leukotriene receptors. Chem. Rev. 111: 6231–6298.
Not in our library10.1021/cr100392s
68.
Yokomizo T., Nakamura M., and Shimizu T. 2018 Leukotriene receptors as potential therapeutic targets. J. Clin. Invest. 128: 2691–2701.
Not in our library10.1172/jci97946
69.
Yamada M., Kita Y., Kohira T., Yoshida K., Hamano F., Tokuoka S. M., and Shimizu T. 2015 A comprehensive quantification method for eicosanoids and related compounds by using liquid chromatography/mass spectrometry with high speed continuous ionization polarity switching. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 995–996: 74–84.
Not in our library10.1016/j.jchromb.2015.05.015
70.
Kono M., Conlon E. G., Lux S. Y., Yanagida K., Hla T., and Proia R. L. 2017 Bioluminescence imaging of G protein-coupled receptor activation in living mice. Nat. Commun. 8: 1163.
Not in our library10.1038/s41467-017-01340-7
71.
Harayama T., and Riezman H. 2018 Understanding the diversity of membrane lipid composition. Nat. Rev. Mol. Cell Biol. 19: 281–296.
Not in our library10.1038/nrm.2017.138
72.
Harayama T., Eto M., Shindou H., Kita Y., Otsubo E., Hishikawa D., Ishii S., Sakimura K., Mishina M., and Shimizu T. 2014 Lysophospholipid acyltransferases mediate phosphatidylcholine diversification to achieve the physical properties required in vivo. Cell Metab. 20: 295–305.
Not in our library10.1016/j.cmet.2014.05.019
73.
Fatty acid remodeling by LPCAT3 enriches arachidonate in phospholipid membranes and regulates triglyceride transport · 2015
No notice
74.
Iizuka-Hishikawa Y., Hishikawa D., Sasaki J., Takubo K., Goto M., Nagata K., Nakanishi H., Shindou H., Okamura T., Ito C., 2017 Lysophosphatidic acid acyltransferase 3 tunes the membrane status of germ cells by incorporating docosahexaenoic acid during spermatogenesis. J. Biol. Chem. 292: 12065–12076.
Not in our library10.1074/jbc.m117.791277
75.
Docosahexaenoic acid preserves visual function by maintaining correct disc morphology in retinal photoreceptor cells · 2017
No notice
76.
Lee H-C., Inoue T., Sasaki J., Kubo T., Matsuda S., Nakasaki Y., Hattori M., Tanaka F., Udagawa O., Kono N., 2012 LPIAT1 regulates arachidonic acid content in phosphatidylinositol and is required for cortical lamination in mice. Mol. Biol. Cell. 23: 4689–4700.
Not in our library10.1091/mbc.e12-09-0673
77.
Nguyen L. N., Ma D., Shui G., Wong P., Cazenave-Gassiot A., Zhang X., Wenk M. R., Goh E. L. K., and Silver D. L. 2014 Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature. 509: 503–506.
Not in our library10.1038/nature13241
78.
Thiés F., Delachambre M. C., Bentejac M., Lagarde M., and Lecerf J. 1992 Unsaturated fatty acids esterified in 2-acyl-1-lysophosphatidylcholine bound to albumin are more efficiently taken up by the young rat brain than the unesterified form. J. Neurochem. 59: 1110–1116.
Not in our library10.1111/j.1471-4159.1992.tb08353.x
79.
Yalagala P. C. R., Sugasini D., Zaldua S. B., Tai L. M., and Subbaiah P. V. 2020 Lipase treatment of dietary krill oil, but not fish oil, enables enrichment of brain eicosapentaenoic acid and docosahexaenoic acid. Mol. Nutr. Food Res. In press.
Not in our library10.1002/mnfr.202000059
80.
Liu L., Bartke N., Van Daele H., Lawrence P., Qin X., Park H. G., Kothapalli K., Windust A., Bindels J., Wang Z., 2014 Higher efficacy of dietary DHA provided as a phospholipid than as a triglyceride for brain DHA accretion in neonatal piglets. J. Lipid Res. 55: 531–539.
Not in our library10.1194/jlr.m045930
81.
da Costa K-A., Rai K. S., Craciunescu C. N., Parikh K., Mehedint M. G., Sanders L. M., McLean-Pottinger A., and Zeisel S. H. 2010 Dietary docosahexaenoic acid supplementation modulates hippocampal development in the Pemt-/- mouse. J. Biol. Chem. 285: 1008–1015.
Not in our library10.1074/jbc.m109.017137
82.
Veglia F., Tyurin V. A., Blasi M., De Leo A., Kossenkov A. V., Donthireddy L., To T. K. J., Schug Z., Basu S., Wang F., 2019 Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature. 569: 73–78.
Not in our library10.1038/s41586-019-1118-2
83.
Antonny B., Vanni S., Shindou H., and Ferreira T. 2015 From zero to six double bonds: phospholipid unsaturation and organelle function. Trends Cell Biol. 25: 427–436.
Not in our library10.1016/j.tcb.2015.03.004
84.
De Santis A., Varela Y., Sot J., D’Errico G., Goñi F. M., and Alonso A. 2018 Omega-3 polyunsaturated fatty acids do not fluidify bilayers in the liquid-crystalline state. Sci. Rep. 8: 16240.
Not in our library10.1038/s41598-018-34264-3
85.
Budin I., de Rond T., Chen Y., Chan L. J. G., Petzold C. J., and Keasling J. D. 2018 Viscous control of cellular respiration by membrane lipid composition. Science. 362: 1186–1189.
Not in our library10.1126/science.aat7925
86.
Regulation of lipid saturation without sensing membrane fluidity · 2020
No notice
87.
Phospholipids that Contain Polyunsaturated Fatty Acids Enhance Neuronal Cell Mechanics and Touch Sensation · 2014
Not checked
88.
Hyvönen M. T., and Kovanen P. T. 2005 Molecular dynamics simulations of unsaturated lipid bilayers: effects of varying the numbers of double bonds. Eur. Biophys. J. 34: 294–305.
Not in our library10.1007/s00249-004-0455-7
89.
Magdeleine M., Gautier R., Gounon P., Barelli H., Vanni S., and Antonny B. 2016 A filter at the entrance of the Golgi that selects vesicles according to size and bulk lipid composition. eLife. 5: e16988.
Not in our library10.7554/elife.16988
90.
Pinot M., Vanni S., Pagnotta S., Lacas-Gervais S., Payet L. A., Ferreira T., Gautier R., Goud B., Antonny B., and Barelli H. 2014 Polyunsaturated phospholipids facilitate membrane deformation and fission by endocytic proteins. Science. 345: 693–697.
Not in our library10.1126/science.1255288
91.
Tiberti M. L., Antonny B., and Gautier R. 2020 The transbilayer distribution of polyunsaturated phospholipids determines their facilitating effect on membrane deformation. Soft Matter. 16: 1722–1730.
Not in our library10.1039/c9sm02107h
92.
Lorent J. H., Levental K. R., Ganesan L., Rivera-Longsworth G., Sezgin E., Doktorova M. D., Lyman E., and Levental I. 2020 Plasma membranes are asymmetric in lipid unsaturation, packing and protein shape. Nat. Chem. Biol. 16: 644–652. [Erratum. 2020. Nat. Chem. Biol. 16: 710.]
Not in our library10.1038/s41589-020-0529-6
93.
Carrillo-Tripp M., and Feller S. E. 2005 Evidence for a mechanism by which ω-3 polyunsaturated lipids may affect membrane protein function. Biochemistry. 44: 10164–10169.
Not in our library10.1021/bi050822e
94.
Stockwell B. R., Friedmann Angeli J. P., Bayir H., Bush A. I., Conrad M., Dixon S. J., Fulda S., Gascón S., Hatzios S. K., Kagan V. E., 2017 Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 171: 273–285.
Not in our library10.1016/j.cell.2017.09.021
95.
Anderson K. E., Kielkowska A., Durrant T. N., Juvin V., Clark J., Stephens L. R., and Hawkins P. T. 2013 Lysophosphatidylinositol-acyltransferase-1 (LPIAT1) is required to maintain physiological levels of PtdIns and PtdInsP2 in the mouse. PLoS One. 8: e58425.
Not in our library10.1371/journal.pone.0058425
96.
Feng C., Lou B., Dong J., Li Z., Chen Y., Li Y., Zhang X., Jiang X-C., and Ding T. 2018 Lysophosphatidylcholine acyltransferase 3 deficiency impairs 3T3L1 cell adipogenesis through activating Wnt/β-catenin pathway. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 1863: 834–843.
Not in our library10.1016/j.bbalip.2018.04.008
97.
Jiang H., Li Z., Huan C., and Jiang X-C. 2019 Macrophage lysophosphatidylcholine acyltransferase 3 deficiency-mediated inflammation is not sufficient to induce atherosclerosis in a mouse model. Front. Cardiovasc. Med. 5: 192.
Not in our library10.3389/fcvm.2018.00192
98.
Lee H-C., Kubo T., Kono N., Kage-Nakadai E., Gengyo-Ando K., Mitani S., Inoue T., and Arai H. 2012 Depletion ofmboa-7, an enzyme that incorporates polyunsaturated fatty acids into phosphatidylinositol (PI), impairs PI 3-phosphate signaling in Caenorhabditis elegans. Genes Cells. 17: 748–757.
Not in our library10.1111/j.1365-2443.2012.01624.x
99.
Li Z., Jiang H., Ding T., Lou C., Bui H. H., Kuo M-S., and Jiang X-C. 2015 Deficiency in lysophosphatidylcholine acyltransferase 3 reduces plasma levels of lipids by reducing lipid absorption in mice. Gastroenterology. 149: 1519–1529.
Not in our library10.1053/j.gastro.2015.07.012
100.
Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion · 2015
No notice
101.
Rong X., Wang B., Palladino E. N. D., de Aguiar Vallim T. Q., Ford D. A., and Tontonoz P. 2017 ER phospholipid composition modulates lipogenesis during feeding and in obesity. J. Clin. Invest. 127: 3640–3651.
Not in our library10.1172/jci93616
102.
Thomas C., Jalil A., Magnani C., Ishibashi M., Queré R., Bourgeois T., Bergas V., Ménégaut L., Patoli D., Le Guern N., 2018 LPCAT3 deficiency in hematopoietic cells alters cholesterol and phospholipid homeostasis and promotes atherosclerosis. Atherosclerosis. 275: 409–418.
Not in our library10.1016/j.atherosclerosis.2018.05.023
103.
Wang B., Rong X., Palladino E. N. D., Wang J., Fogelman A. M., Martín M. G., Alrefai W. A., Ford D. A., and Tontonoz P. 2018 Phospholipid remodeling and cholesterol availability regulate intestinal stemness and tumorigenesis. Cell Stem Cell. 22: 206–220.e4.
Not in our library10.1016/j.stem.2017.12.017
104.
Ben M’barek K., Ajjaji D., Chorlay A., Vanni S., Forêt L., and Thiam A. R. 2017 ER membrane phospholipids and surface tension control cellular lipid droplet formation. Dev. Cell. 41: 591–604.e7.
Not in our library10.1016/j.devcel.2017.05.012
105.
Barquissau V., Ghandour R. A., Ailhaud G., Klingenspor M., Langin D., Amri E-Z., and Pisani D. F. 2017 Control of adipogenesis by oxylipins, GPCRs and PPARs. Biochimie. 136: 3–11.
Not in our library10.1016/j.biochi.2016.12.012
106.
Johansen A., Rosti R. O., Musaev D., Sticca E., Harripaul R., Zaki M., Çağlayan A. O., Azam M., Sultan T., Froukh T., 2016 Mutations in MBOAT7, encoding lysophosphatidylinositol acyltransferase I, lead to intellectual disability accompanied by epilepsy and autistic features. Am. J. Hum. Genet. 99: 912–916.
Not in our library10.1016/j.ajhg.2016.07.019
107.
Xia Y., Huang C-X., Li G-Y., Chen K-H., Han L., Tang L., Luo H-q., and Bao M-H. 2019 Meta-analysis of the association between MBOAT7 rs641738, TM6SF2 rs58542926 and nonalcoholic fatty liver disease susceptibility. Clin. Res. Hepatol. Gastroenterol. 43: 533–541.
Not in our library10.1016/j.clinre.2019.01.008
108.
Helsley R. N., Varadharajan V., Brown A. L., Gromovsky A. D., Schugar R. C., Ramachandiran I., Fung K., Kabbany M. N., Banerjee R., Neumann C. K., 2019 Obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease. eLife. 8: e49882.
Not in our library10.7554/elife.49882
109.
LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover · 2020
No notice
110.
Hayashi Y., Yamano M., Kono N., Arai H., Fujiwara Y., and Ichi I. 2020 Phosphorylation of Elovl5 changes its substrate preference to synthesize Mead acid in response to essential fatty acid deficiency. bioRxiv. 10.1101/2020.01.31.929224.
Not in our library
111.
Omega-3 Fatty Acids Modulate TRPV4 Function through Plasma Membrane Remodeling · 2017
Not checked
112.
Niphakis M. J., Lum K. M., Cognetta A. B., Correia B. E., Ichu T-A., Olucha J., Brown S. J., Kundu S., Piscitelli F., Rosen H., 2015 A global map of lipid-binding proteins and their ligandability in cells. Cell. 161: 1668–1680.
Not in our library10.1016/j.cell.2015.05.045
113.
Doll S., Proneth B., Tyurina Y. Y., Panzilius E., Kobayashi S., Ingold I., Irmler M., Beckers J., Aichler M., Walch A., 2017 ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13: 91–98.
Not in our library10.1038/nchembio.2239
114.
Nakakuki M., Kawano H., Notsu T., Imada K., Mizuguchi K., and Shimano H. 2014 A novel processing system of sterol regulatory element-binding protein-1c regulated by polyunsaturated fatty acid. J. Biochem. 155: 301–313.
Not in our library10.1093/jb/mvu019
115.
Park H. G., Park W. J., Kothapalli K. S. D., and Brenna J. T. 2015 The fatty acid desaturase 2 (FADS2) gene product catalyzes Δ4 desaturation to yield n-3 docosahexaenoic acid and n-6 docosapentaenoic acid in human cells. FASEB J. 29: 3911–3919.
Not in our library10.1096/fj.15-271783

Cited by papers we hold 2

Metabolic cell death in cancer: ferroptosis, cuproptosis, disulfidptosis, and beyond · 2024
No notice
Lipid droplets and polyunsaturated fatty acid trafficking: Balancing life and death · 2023
Corrected

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.